IRB #

IRB00008541

Title

A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma

Principal Investigator

Jacqueline Vuky

Study Purpose

The purpose of this study is to examine the effects of a new medication (DN24-02) when used to treat those who just had surgery to treat their urothelial cancer (that expresses HER2/neu)

Medical Condition(s)

Urolthelial cancer

Eligibility Criteria

Males and Females, 18 and older, with urotherlial cancer that expresses HER2/neu.

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

Subjects will be followed for life.

Minors Included

No

Contact

Community Oncology 503.601.7641

Sponsor

Dendreon Corporation

Recruitment End

12/31/2013

Compensation Provided

No